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Background: Microsatellite instability (MSI) is a mutational signature that is the hallmark of Lynch syndrome, and MSI testing 
is a cost-effective method to screen the disease. Since there is no enough data about MSI status and associated clinicopathologic 
features of hereditary nonpolyposis colorectal cancer (HNPCC) in Iran, our study is a new trial to describe them in center of Iran 
(Isfahan). Materials and Methods: It is a descriptive retrospective study to screen HNPCC families using Amsterdam II criteria 
in Central Iran within 2000-2013. For MSI testing, we used a commercially available kit evaluating mononucleotide markers (BAT-
25, BAT-26, MON0-27, NR-21 and NR-24). After a fluorescent multiplex polymerase chain reaction amplification of the markers, 
samples were sequenced to fragment analysis. Data analysis was performed using SPSS 16 software (SPSS Inc., Chicago, IL, USA). 
Results: Overall, 31 of 45 screened HNPCC families were eventually included to MSI testing. Totally, 9/31 patients (29.0%) showed MSI 
in their tumor tissues. BAT-26 was the most instable marker with instability in 7/24 MSI tumors (29.2%). The mean age at diagnosis 
in microsatellite stable (MSS), MSI-Low (MSI-L), and MSI-High (MSI-H) probands was respectively 44.7 (standard deviation [SD] 
= 11.83), 51.7 (SD = 16.17), and 36.0 (SD = 3.41) years. The most common tumor sites in MSS, MSI-L, and MSI-H probands were 
rectosigmoid (~72.8%), rectum (66.7%) and right colon (50.0%), respectively. Of 186 cancer patients among 31 HNPCC families, 
86 patients (46.2%) had colorectal cancer (CRC) and 100 patients (53.8%) had extracolonic cancers. The average of CRC affected 
members among MSS, MSI-L, and MSI-H groups of our HNPCC families was 2.2 (SD = 1.30), 3.3 (SD = 3.21), and 4.7 (SD = 2.42) 
patients per family, respectively. Stomach with 18.3% and 26.7% of all extracolonic cancers were most common involved organ in 
MSS and MSI-H families, respectively. Conclusion: Our different molecular results could be suggested to describe HNPCC families 
based on some new molecular mechanisms leading to MSS HNPCC phenotypes. Meanwhile, more evaluations within our population 
are recommended.
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detectable as a change in allele size between tumor and 
normal DNA. Expansion or contraction of these repeating 
sequences due to increase or decrease in the repeat units 
gives rise to what is referred to as MSI. Almost 15-24% of 
all CRCs show MSI[6] while in Lynch syndrome, including 
nearly 3% of all CRCs, MSI is presented in almost all of 
the cases[5] containing 20-25% of all MSI-CRCs. The rest 
CRCs (75-80%) are due to the acquired loss of DNA MMR 
activity caused by promoter hypermethylation of the 
hMLH1 gene.[7] MSI is identified by polymerase chain 
reaction (PCR) amplification of specific microsatellite 
repeats. The existence of instability is determined by 
comparing the length of nucleotide repeats in tumor cells 
and normal cells.[4]
One of the major clinical implications of finding MSI 
tumors is that it is a cost-effective method to screen for 
INTRODUCTION
Both genetic and epigenetic alterations have the essential 
role to evolve tumorigenesis phenomena. Chromosomal 
instability, microsatellite instability (MSI) and CpG 
island methylator phenotype pathways are responsible 
for genetic instability in colorectal cancer (CRC).[1,2]
Microsatellite instability is genomic instability of short 
tandem repeats. These are stretches of repeating units of 
1-5 base pairs with 25-60 bp in length and are commonly 
in the form of CA (bp) that are distributed throughout the 
genome.[3] Actually, MSI is a molecular fingerprinting[4] or 
a mutational signature that is the hallmark of CRC. It has 
evolved as a result of inactivation of the DNA mismatch 
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Lynch syndrome. Once MSI tumors are detected, they can 
then be tested for the germ-line mutation of the missing 
MMR protein. It has a great impact on survival outcomes 
for patients and their families through early introduction of 
genetic counseling and cancer screening practices.[8]
Colorectal cancer is the third most prevalent and the third 
leading cause of cancer-related deaths in Iran[9] and its 
incidence has been increased over the last three decades 
in the Country.[10] Since there is no enough data about 
MSI status and associated clinicopathologic features of 
hereditary nonpolyposis colorectal cancer (HNPCC) in 




We used a descriptive retrospective study to identify 
CRC patients at risk Lynch syndrome in Central Iran. Our 
samples were screened from 1659 CRC patients registered 
in Poursina Hakim Research Center (PHRC), an referral 
gastroenterology clinic in Central part of Iran, Isfahan, 
during about 14 years, from 2000 to end of 2013. We called 
patients who met Amsterdam II criteria contain: Three or 
more relatives with an associated cancer (CRC, or cancer 
of the endometrium, small intestine, ureter or renal pelvis, 
hepatobiliary tract, brain, skin, breast, and etc); two or 
more successive generations affected; one or more relatives 
diagnosed before the age of 50 years; one should be a first-
degree relative of the other two; familial adenomatous 
polyposis should be excluded in cases of CRC; tumors 
should be verified by pathologic examination.[11]
Microsatellite instability testing
For MSI analysis, we need both tumor and healthy tissue 
DNA. The National Cancer Institute recommended a panel 
included two mononucleotide markers (BAT25 and BAT26) 
and three dinucleotide markers (D2S123, D5S346 and 
D17S250) to analyze MSI.[12,13] According to some studies, 
mononucleotide markers have higher specificity and similar 
or better sensitivity than dinucleotide markers to identify 
an MSI-High (MSI-H) phenotype.[14,15]
We used a commercially kit from Promega Corporation 
(MSI Analysis System, Version 1.2, Madison, USA) that 
evaluates just mononucleotide markers (BAT-25, BAT-26, 
MON0-27, NR-21 and NR-24). Moreover, it contains two 
pentanucleotide markers (Penta C and Penta D) as specimen 
identification markers to detect specimen mix-ups. After a 
fluorescent multiplex PCR amplification of the markers, 
samples are sequenced to fragment analysis. In this process, 
allelic profiles of amplified microsatellite markers are 
compared from matching pairs of test samples, which may 
be MMR-deficient, and normal tissue samples. If new alleles 
are observed in the tumor sample without their presence 
in the corresponding normal sample, MSI is confirmed. 
Tumors are considered as MSI-H if at-least two markers of 
the quintet show instability and MSI-Low (MSI-L) if only 
one marker is unstable.
Data analysis
We analyzed the obtained data by SPSS 16 software package 
(SPSS Inc., Chicago, IL, USA).
Ethical approval
Ethical approval was received from the medical ethics 
committee of Shahrekord University of Medical Sciences 
(Research project Number: 91-01-70-1364). The research was 
carried out according to principles set out in the Declaration 
of Helsinki 1964 and all subsequent revisions, informed 
consent was obtained, and the privacy and confidentiality 
were observed throughout the study.
RESULTS
Altogether 1659 CRC patients had been registered in 
PHRC within a 14-year period (2000-2013). Of these 
413 patients (24.9%) were ≤50 years at diagnosis. 
Among 219/413 successful calls, 45 HNPCC families 
were eventually selected using Amsterdam II criteria 
for molecular testing stage of which 14 probands were 
omitted due to lack of their tumor tissues or being 
unwilling for incorporation.
Of 31 studied HNPCC probands, 9 patients (~29%) showed 
MSI in their tumor tissues (6 patients [19.4%] with MSI-H). 
The proportion of male to female in microsatellite stable 
(MSS) probands was 11/11 = 1, and in MSI probands it 
was 6/3 = 2. Among quasimononucleotide markers used 
in MSI testing, BAT-26 was the most instable marker with 
instability in 7/31 MSI tumors (22.6%), both BAT-25 and 
NR-24 markers showed instability in 6/31 (19.3%), and both 
MONO-27 and NR-21 markers were instable in 5/31 (16.1%) 
MSI-CRC tumors.
In 4/6 MSI-H patients all markers were instable (66.6%), 
and among two rest patients, one showed instability in 
four markers (except MONO-27) and the other showed 
instability in two of them (BAT-26 and NR-24) [Figures 1 
and 2].
The mean age at diagnosis in MSS, MSI-L, and MSI-H 
probands was respectively 44.7, 51.7, and 36.0 years 
(P = 0.123).
The most common tumor sites in CRC probands with MSS, 
MSI-L, and MSI-H phenotype were rectosigmoid (~72.8%), 
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rectum (~66.7%), and right colon (50.0%), respectively. 
Although in MSS probands, just 18.2% of the CRC tumors 
were located in the right side of the splenic flexure, in MSI-H 
tumors it was about 70%.
Overall, there was history of 186 cancer patients within 
our 31 HNPCC families (103 men or 55.4%) of which 
86 patients (46.2%) had been affected by CRC tumors 
and 100 patients (53.8%) by extracolonic cancers. The 
average of cancer patients among MSS, MSI-L, and 
MSI-H groups of the HNPCC families was 5.4, 7.7, 
and 6.0 patients per family, respectively (P = 0.12). 
Moreover, the average of CRC affected members among 
MSS, MSI-L, and MSI-H groups of our HNPCC families 
was 2.2, 3.3, and 4.7 patients per family, respectively 
(P = 0.014). Meanwhile, the average of affected members 
by extracolonic cancers in these three groups was 3.2, 
4.3, and 1.3 patients per family (P = 0.045). Moreover, 
the proportion of CRC patients to all cancer patients was 
40.3%, 41.7%, and 65.1% among MSS, MSI-L, and MSI-H 
groups of these families, respectively.
Among extracolonic cancers, stomach, lung, and breast 
with respectively: 18.3, 15.5, and 11.3% were most 
common involved organs in MSS group of the studied 
families. In males of this group, lung and stomach with 
28.9 and 23.7%, and among their females, breast and 
brain with 24.2 and 15.2%, respectively, were the most 
prevalent involved organs by extracolonic cancers. 
Moreover in MSI-L families, breast and brain equally with 
21.4%, and hepatobiliary tract with 14.3%, and in MSI-H 
families, stomach and hematopoietic system with 26.7 and 
20.0%, respectively, were evaluated as the most common 
involved organs. Among the males of MSI-H families, 
stomach and hematopoietic system with 25.0 and 33.3% 
were the most prevalent involved organs by extracolonic 
cancers. While in females of this group, 84.2% of cancers 
were CRC, and then breast, uterus, and hepatobiliary 
tract equally with 33.3% of all extracolonic cancers were 
the most common involved organs [Table 1].
Overall, respectively, 8, 10, and 18 different organs were 
affected within MSI-H, MSI-L, and MSS families.
According to pathologic reports of the probands’ tumors, 
the most common pathologic phenotype in MSS and MSI-L 
CRC tumors was “well differentiated Adenocarcinoma” 
with 31.8 and 66.7%, respectively; while in MSI-H CRC 
tumors, “moderate differentiated Adenocarcinoma” with 
50.0% was evaluated as the most common pathologic 
phenotype.
Moreover, 63.6% of MSS CRC tumors of the probands 
have been diagnosed in late pathologic TNM stages 
(stages III or IV) while 100% and 83.3% of MSI-L and 
MSI-H CRC tumors, respectively were diagnosed in 
these late stages.
Overall 12/31 (38.7%) of the probands had been deceased at 
our study time. The proportion of the deceased probands 
among MSS, MSI-L, and MSI-H groups was 31.8%, 100%, 
and 33.3%, respectively.
The survival period of the probands, the interval between 
diagnosis time and date of death or date of analyses were 
averagely calculated for MSS, MSI-L, and MSI-H group of the 
probands as: 6.1, 2.0, and 5.8 years, respectively (P = 0.341).
Figure 1: Frequency of five quasimononucleotide markers in 31 HNPCC tumors 
according to instability state. HNPCC = Hereditary non-polyposis colorectal 
cancer
Figure 2: An example of microsatellite instability in one of our DNA 
electropherogram Traces: It is related to three quasimononucleotide markers 
including NR-21, BAT-25, and MONO-27, indicating normal stability state in 
upper sample (153453 3) as normal healthy tissue, and instability state in every 
three markers in lower sample (153454 4) as tumor tissue
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DISCUSSION
We evaluated in this study, tumor MSI state in index 
CRC patients among 31 identified HNPCC families 
within Central Iran for the 1st time. Screening process was 
performed according to genetic counseling of at-risk families 
for HNPCC given the Amsterdam II criteria. Somewhat high 
prevalence of familial CRC among our population and the 
limitation of our financial resources made us using these 
more specific criteria. Meanwhile, we had not an explicit 
visage of molecular aspects in our HNPCC families to 
establish a systematic, population-based screening program 
in our population. So, running this study could help us to 
elucidate partially this vague state.
Microsatellite instability prevalence
Sole 29% of screened CRC probands showed MSI in 
their tumor tissues of which 19.4% demonstrated MSI-H. 
Apparently, it is lower than similar studies on different 
populations around the world. For example, in a recent 
Spanish study, 80% of CRC patients with Amsterdam or 
Bethesda criteria had MSI positive tumors.[16] In addition 
in another study, 59.4% of Amsterdam I-positive CRC 
probands had MSI tumors.[17] Although some Iranian studies 
Table 1: Percentage of different types of cancer among Amsterdam-II positive families according to MSI status and gender
MSI status Cancer type Gender
Male Female
Frequency Percentage Frequency Percentage
MSS Colorectal 28 42.4 20 37.7
Kidney 1 1.5 0 0.0
Brain 1 1.5 5 9.4
Skin 2 3.0 1 1.9
Thyroid 2 3.0 0 0.0
Hematopoietic system 1 1.5 1 1.9
Testis 1 1.5 0 0.0
Bone 1 1.5 1 1.9
Pancreas 1 1.5 0 0.0
Nasopharynx 0 0.0 1 1.9
Intestine 1 1.5 4 7.5
Stomach 9 13.6 4 7.5
Hepatobiliary tract 2 3.0 3 5.7
Breast 0 0.0 8 15.1
Lung 11 16.7 0 0.0
Prostate 3 4.5 0 0.0
Uterus 0 0.0 4 7.5
Bladder 2 3.0 1 1.9
Total 66 100 53 100
MSI-L Colorectal 6 46.2 4 36.4
Brain 2 15.4 1 9.1
Hematopoietic system 0 0.0 1 9.1
Testis 1 7.7 0 0.0
Intestine 0 0.0 1 9.1
Stomach 0 0.0 1 9.1
Hepatobiliary tract 2 15.4 0 0.0
Breast 0 0.0 3 27.3
Lung 1 7.7 0 0.0
Prostate 1 7.7 0 0.0
Total 13 100 11 100
MSI-H Colorectal 12 50.0 16 84.2
Hematopoietic system 3 12.5 0 0.0
Stomach 4 16.7 0 0.0
Hepatobiliary tract 1 4.2 1 5.3
Breast 0 0.0 1 5.3
Lung 2 8.3 0 0.0
Prostate 2 8.3 0 0.0
Uterus 0 0.0 1 5.3
Total 24 100 19 100
MSS = Microsatellite stable; MSI = Microsatellite instability; MSI-L = Microsatellite instability-low; MSI-H = Microsatellite instability-high
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have shown high relative frequency of MSI among sporadic 
CRC tumors,[18,19] given the lack of enough data regard 
to MSI status among Iranian HNPCC patients, it seems 
more evaluation is necessary. Meanwhile, more molecular 
analyses are advisable to explore possible, unknown DNA 
loci among MSS patients.
As above,  the  frequency of  instabi l i ty  among 
5 quasimononucleotide markers of pentaplex Promega 
panel in our MSI-CRC tumors was between 19.2% (MONO-
27 and NR-21) and 29.2% (BAT-26). In other words, all 
of these five markers were determinant to diagnose MSI 
status of our HNPCC probands. Nevertheless, different 
studies have presented variable molecular phenotypes 
for these markers. For example, in a recent Iranian 
study on 80 sporadic CRC patients, the most instable 
markers were NR-21, NR-24 with 45%. In this study, 
NR-27 with zero and BAT-26 with 6.7% instability were 
the most stable markers.[20] Other similar studies among 
different ethnic populations around the world have 
shown various results.[21-23] Apparently, instability feature 
of mononucleotide markers differs among different 
populations due to an ethnic variation in frequency of 
different mononucleotide markers. Moreover, may be it 
differs in sporadic CRCs compared to HNPCC CRCs, an 
issue about which more evaluations are necessary.
Clinicopathologic features
Microsatellite instability-H group of our probands had 
been affected averagely 7 years earlier than MSS group. 
Moreover, the proportion of CRC tumors localizing in the 
right colon among MSI-H probands to MSS group was near 
4-fold (70% vs. 18%), while all of MSI-L tumors localized 
in distal colon. This is like to other similar studies among 
different populations in which there are findings for early 
onset and proximal localization of majority of MSI-H 
tumors.[17,24-26]
The average of CRC patients among the MSI-H families 
was significantly >2 other groups (4.7 patients vs. 3.3 and 
2.2 in MSI-L and MSS families, respectively). Meanwhile, 
the average of extracolonic cancer patients among the MSS 
families was about 2.5-fold of MSI-H families (3.2 vs. 1.3). 
Similar previous studies have presented more relative 
frequency of CRC patients among Lynch syndrome-affected 
families compared to those affected by familial colorectal 
cancers.[17,27-29]
The most prevalent extracolonic cancers among males of 
MSS families were in lung and stomach, and among their 
females in breast and brain, respectively. Although gastric 
and breast cancers have been the most common cancers 
among Iranian population in recent decade,[30] apparently 
some unknown inheritable molecular changes are accused 
for familial aggregation of less prevalent cancers like 
brain in these families. Meanwhile, similar environmental 
conditions in interaction with some particular genotypes 
may lead to familial aggregation of some less inheritable 
cancers including lung and hematopoietic system.[31,32] The 
most prevalent extracolonic cancers among males and 
females of MSI-H families were in stomach and breast, 
respectively, compatible with current epidemiologic pattern 
of cancers among Iranian general population.[30] It again 
could determine significance of the environmental factors 
in tumorgenesis among these families in interaction with 
some molecular phenotypes.
As we mentioned, of 18 different organs involved 
in cancer patients among the families, just 8 organs 
were affected within MSI-H families. Whereas, 18 and 
10 different involved organs were seen among MSS 
and MSI-L families, respectively. Apparently, familial 
aggregation of distinct cancers involving multiple organs 
among MSS HNPCC families is more extensive than 
MSI group. It could correspond to different underlying 
molecular pathology of MSS probands compared to MSI 
group of them, suggesting a new cancer-causing gene or 
genes responsible for tumorigenesis in multiple organs 
than only colorectal tract or a few associated organs. It 
is, apparently, different from some similar studies on 
other populations, discussing a heterogeneous feature 
of the disease among various communities.[17] It could 
also discuss new definitions to describe HNPCC families 
based on some new molecular phenotypes; an issue 
around which more evaluations should be administered. 
Moreover, multiple organ involvement among MSS 
HNPCC families or “familial CRC type X” families 
according to some authors[27,29,33] suggests that the current 
cancer screening guidelines for HNPCC like annual 
colonoscopy or transvaginal ultrasound is somewhat 
questionable.
“Well differentiated Adenocarcinoma” was the most 
prevalent pathologic feature of the MSS CRC tumors; 
while among MSI-H CRC tumors, the most common was 
“moderate differentiated Adenocarcinoma”. According to 
different studies, MSS HNPCC patients have had less often 
poorly differentiated Adenocarcinoma in comparison to 
MSI HNPCC patients.[17,27,29]
We found more MSI probands in late pathologic TNM 
stages than MSS group while there was no statistical 
difference between them regard to their survival period. 
It could be corresponded to better survival among MSI 
group of the probands than MSS group of them; the 
fact that other similar studies have pointed to it.[6,25,34] 
Meanwhile, more evaluations within our population are 
recommended.
Zeinalian, et al.: Tumor microsatellite instability in patients at risk for Lynch syndrome
Journal of Research in Medical Sciences | February 2015 |159
ACKNOWLEDGMENT
This article is concluded of a PhD thesis (Project No: 91-01-70-
1364) in Shahrekord University of Medical Sciences. We appreciate 
the helpful cooperation of all health workers in Poursina Hakim 
Research Institute, genetic department of Isfahan Medicine School 
and Cellular and Molecular Research Center of Shahrekord 
University of Medical Sciences to technical consultation.
AUTHOR’S CONTRIBUTION
MZ is the first author. MHE is corresponding author. MHCh 
contributed as the main guide master. RS contributed as the 
main consultant master, and MK contributed as a technical 
consultant.
REFERENCES
1. Armaghany T, Wilson JD, Chu Q, Mills G. Genetic alterations in 
colorectal cancer. Gastrointest Cancer Res 2012;5:19-27.
2. Markowitz SD, Bertagnolli MM. Molecular origins of cancer: 
Molecular basis of colorectal cancer. N Engl J Med 2009;361: 
2449-60.
3. Sameer AS. Colorectal cancer: Molecular mutations and 
polymorphisms. Front Oncol 2013;3:114.
4. Vilar E, Gruber SB. Microsatellite instability in colorectal cancer-the 
stable evidence. Nat Rev Clin Oncol 2010;7:153-62.
5. Boland CR, Koi M, Chang DK, Carethers JM. The biochemical basis 
of microsatellite instability and abnormal immunohistochemistry 
and clinical behavior in Lynch syndrome: From bench to bedside. 
Fam Cancer 2008;7:41-52.
6. Desselle F, Verset G, Polus M, Louis E, Van Daele D. Lynch 
syndrome and microsatellite instability: A review. Rev Med Liege 
2012;67:638-43.
7. Cunningham JM, Christensen ER, Tester DJ, Kim CY, Roche 
PC, Burgart LJ, et al. Hypermethylation of the hMLH1 promoter 
in colon cancer with microsatellite instability. Cancer Res 
1998;58:3455-60.
8. Wu C, Bekaii-Saab T. CpG island methylation, microsatellite 
instability, and BRAF mutations and their clinical application 
in the treatment of colon cancer. Chemother Res Pract 
2012;2012:359041.
9. Mousavi SM, Gouya MM, Ramazani R, Davanlou M, Hajsadeghi 
N, Seddighi Z. Cancer incidence and mortality in Iran. Ann Oncol 
2009;20:556-63.
10. Haghighi MM, Javadi GR, Parivar K, Milanizadeh S, Zali N, 
Fatemi SR, et al. Frequent MSI mononucleotide markers for 
diagnosis of hereditary nonpolyposis colorectal cancer. Asian Pac 
J Cancer Prev 2010;11:1033-5.
11. Vasen HF, Watson P, Mecklin JP, Lynch HT. New clinical criteria 
for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch 
syndrome) proposed by the International Collaborative group on 
HNPCC. Gastroenterology 1999;116:1453-6.
12. Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, 
Eshleman JR, Burt RW, et al. A National Cancer Institute Workshop 
on Microsatellite Instability for cancer detection and familial 
predisposition: Development of international criteria for the 
determination of microsatellite instability in colorectal cancer. 
Cancer Res 1998;58:5248-57.
13. Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, 
Rüschoff J, et al. Revised Bethesda Guidelines for hereditary 
nonpolyposis colorectal cancer (Lynch syndrome) and 
microsatellite instability. J Natl Cancer Inst 2004;96:261-8.
14. Murphy KM, Zhang S, Geiger T, Hafez MJ, Bacher J, Berg KD, 
et al. Comparison of the microsatellite instability analysis system 
and the Bethesda panel for the determination of microsatellite 
instability in colorectal cancers. J Mol Diagn 2006;8:305-11.
15. Agostini M, Enzo MV, Morandi L, Bedin C, Pizzini S, Mason S, 
et al. A ten markers panel provides a more accurate and complete 
microsatellite instability analysis in mismatch repair-deficient 
colorectal tumors. Cancer Biomark 2010;6:49-61.
16. Wielandt AM, Zárate AJ, Hurtado C, Orellana P, Alvarez K, 
Pinto E, et al. Lynch syndrome: Selection of families by 
microsatellite instability and immunohistochemistry. Rev Med 
Chil 2012;140:1132-9.
17. Valle L, Perea J, Carbonell P, Fernandez V, Dotor AM, Benitez J, 
et al. Clinicopathologic and pedigree differences in amsterdam 
I-positive hereditary nonpolyposis colorectal cancer families 
according to tumor microsatellite instability status. J Clin Oncol 
2007;25:781-6.
18. Mokarram P, Rismanchi M, Alizadeh Naeeni M, Mirab Samiee S, 
Paryan M, Alipour A, et al. Microsatellite instability typing in 
serum and tissue of patients with colorectal cancer: Comparing 
real time PCR with hybridization probe and high-performance 
liquid chromatography. Mol Biol Rep 2014;41:2835-44.
19. Brim H, Mokarram P, Naghibalhossaini F, Saberi-Firoozi M, 
Al-Mandhari M, Al-Mawaly K, et al. Impact of BRAF, MLH1 on 
the incidence of microsatellite instability high colorectal cancer in 
populations based study. Mol Cancer 2008;7:68.
20. Esmailnia G, Montazer-Haghighi M, Javadi G, Parivar K, Zali M. 
Microsatellite instability markers status in colorectal cancer. 
Zahedan J Res Med Sci (ZJRMS) 2014;16:25-8.
21. Faghani M, Fakhrieh Asl S, Mansour-Ghanaei F, Aminian K, 
Tarang A, Seighalani R, et al. The Correlation between microsatellite 
instability and the features of sporadic colorectal cancer in the 
North part of Iran. Gastroenterol Res Pract 2012;2012:756263.
22. Ichikawa A, Sugano K, Fujita S. DNA variants of BAT-25 in 
Japanese, a locus frequently used for analysis of microsatellite 
instability. Jpn J Clin Oncol 2001;31:346-8.
23. Pyatt  R,  Chadwick RB, Johnson CK, Adebamowo C, 
de la Chapelle A, Prior TW. Polymorphic variation at the BAT-25 
and BAT-26 loci in individuals of African origin. Implications for 
microsatellite instability testing. Am J Pathol 1999;155:349-53.
24. Bapat B, Lindor NM, Baron J, Siegmund K, Li L, Zheng Y, et al. 
The association of tumor microsatellite instability phenotype with 
family history of colorectal cancer. Cancer Epidemiol Biomarkers 
Prev 2009;18:967-75.
25. Kloor M, Staffa L, Ahadova A, von Knebel Doeberitz M. Clinical 
significance of microsatellite instability in colorectal cancer. 
Langenbecks Arch Surg 2014;399:23-31.
26. Oh JR, Kim DW, Lee HS, Lee HE, Lee SM, Jang JH, et al. 
Microsatellite instability testing in Korean patients with colorectal 
cancer. Fam Cancer 2012;11:459-66.
27. Lindor NM, Rabe K, Petersen GM, Haile R, Casey G, Baron J, et al. 
Lower cancer incidence in Amsterdam-I criteria families without 
mismatch repair deficiency: Familial colorectal cancer type X. 
JAMA 2005;293:1979-85.
28. Renkonen E, Zhang Y, Lohi H, Salovaara R, Abdel-Rahman WM, 
Nilbert M, et al. Altered expression of MLH1, MSH2, and MSH6 
in predisposition to hereditary nonpolyposis colorectal cancer. J 
Clin Oncol 2003;21:3629-37.
29. Llor X, Pons E, Xicola RM, Castells A, Alenda C, Piñol V, et al. 
Differential features of colorectal cancers fulfilling Amsterdam 
criteria without involvement of the mutator pathway. Clin Cancer 
Res 2005;11:7304-10.
Zeinalian, et al.: Tumor microsatellite instability in patients at risk for Lynch syndrome
Journal of Research in Medical Sciences| February 2015 | 160
Source of Support: Nil, Conflict of Interest: No conflict of interests.
30. Kolahdoozan S, Sadjadi A, Radmard AR, Khademi H. Five 
common cancers in Iran. Arch Iran Med 2010;13:143-6.
31. Ridge CA, McErlean AM, Ginsberg MS. Epidemiology of lung 
cancer. Semin Intervent Radiol  2013;30:93-8.
32. Yoder LH. Lung cancer epidemiology. Med Surg Nurs 
2006;15:171-4.
33. Lynch HT, Lynch PM, Lanspa SJ, Snyder CL, Lynch JF, Boland CR. 
Review of the Lynch syndrome: History, molecular genetics, 
screening, differential diagnosis, and medicolegal ramifications. 
Clin Genet 2009;76:1-18.
34. Zhang X, Li J. Era of universal testing of microsatellite instability 
in colorectal cancer. World J Gastrointest Oncol 2013;5:12-9.
